Close
Novotech
Jabsco PureFlo 21 Single Use

Lilly To Provide Detailed Update Of Pipeline And R&D Strategy At Upcoming Investment Community Meeting

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Eli Lilly and Company announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media.

World pharma today/Industry reports/- The meeting will take place Tuesday, May 24, 2016, from 10:00 a.m. (EDT) until approximately 3:00 p.m., inNew York City.

The investment community meeting will focus on Lilly’s research and development opportunities in diabetes, immunology, oncology and pain. It follows a similar meeting in December 2015 to review the company’s broad Alzheimer’s disease pipeline. The presentations will include discussion of new indications and line extensions for a number of established products as well as late-stage and select earlier-stage new molecular entities. There will be Q&A opportunities throughout the meeting.

A live webcast of the Lilly investment community meeting, along with presentation slides, will be available through a link on the investor section of Lilly’s website at https://investor.lilly.com/events.cfm. An audio replay will also be available for approximately one month.

Because of limited space, advance registration is required. Media interested in attending in person should contactMolly McCully at (317) 478-5423. Investors interested in attending should contact Edward Villacorta at (317) 433-1805.

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »